What Is Edgewise Therapeutics, Inc. (EWTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Edgewise Therapeutics, Inc.'s intrinsic value is estimated at $21.18. Trading at its current price of $40.83, the valuation engine raises significant caution: 8 of 10 models flag downside risk, projecting an average implied return of -48.1%. Notably, First Chicago sees the most upside at +22.0% (fair value: $49.80), while ML-RIV is the most conservative at -96.7% ($1.35). The spread between these extremes — +118.6% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About EWTX?
10 of 13 models are currently active for EWTX. Of these, 2 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates EWTX's intrinsic value at $17.74, implying -56.6% downside from the current price. See which stocks rank higher →
How Does EWTX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, EWTX ranks #276 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Edgewise Therapeutics, Inc., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.
Is EWTX a Value Trap?
CirclFi's Value Trap algorithm assigns EWTX a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Edgewise Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Edgewise Therapeutics, Inc. scores 4.5 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +118.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every EWTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across EWTX's 10 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad